Therapeutic Opportunities for TNIK & ISM18-055 (IMAGE)

InSilico Medicine

Therapeutic Opportunities for TNIK & ISM18-055

Caption

Research reveals that TNIK has broad potential as a therapeutic target for some of the most pervasive aging-related diseases, including fibrosis, cancer, obesity, and Alzheimer’s. The findings could guide the development of new therapeutics. The lead drug in Insilico’s pipeline, INS018_055, is an AI-designed TNIK inhibitor being advanced as a treatment for the deadly lung disease idiopathic pulmonary fibrosis (IPF) and is currently in Phase II trials with patients.

Credit

Insilico Medicine

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.